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Transglutaminase 2 (TG2) is a Ca2-dependent cross-linking
enzyme involved in the pathogenesis of CD.We have previously
characterized a panel of anti-TG2 mAbs generated from gut
plasma cells of celiac patients and identified four epitopes
(epitopes 1–4) located in theN-terminal part of TG2. Binding of
the mAbs induced allosteric changes in TG2. Thus, we aimed to
determine whether these mAbs could influence enzymatic
activity through modulation of TG2 susceptibility to oxidative
inactivation andCa2 affinity. All tested epitope 1mAbs, as well
as 679-14-D04, which recognizes a previously uncharacterized
epitope, prevented oxidative inactivation and increased Ca2
sensitivity of TG2.We have identified crucial residues for bind-
ing of 679-14-D04 located within a Ca2 binding site. Epitope 1
mAbs and 679-14-D04, although recognizing separate epitopes,
behaved similarly when assessing their effect onTG2 conforma-
tion, suggesting that the shared effects on TG2 function can be
explained by induction of the same conformational changes.
None of themAbs targeting other epitopes showed these effects,
but epitope 2 mAbs reduced the rate of TG2-catalyzed reac-
tions. Collectively, these effects could be relevant to the patho-
genesis of CD. In A20 B cells transduced with TG2-specific
B-cell receptor, epitope 2-expressing cells had poorer uptake of
TG2-gluten complexes and were less efficient in gluten epitope
presentation to T cells than cells expressing an epitope 1 recep-
tor. Thus, the ability of epitope 1-targeting B cells to keep TG2
active and protected from oxidation might explain why genera-
tion of epitope 1-targeting plasma cells seems to be favored in
celiac patients.
TG22 is a ubiquitously expressed, Ca2-dependent enzyme,
which reacts with glutamine residues in a sequence-specific
manner and covalently links the side chain carbonyl group to a
primary amine (transamidation) (1). Typically, the amino
group is provided by a protein lysine residue, in which case the
reaction generates protein-protein cross-links, thought to be
important for stabilization of extracellular matrix structures.
Alternatively, the enzyme can hydrolyze the target glutamine
residue, thereby converting it into a glutamic acid residue
(deamidation). TG2 is implicated in the pathogenesis of a wide
range of human diseases (2–5). Among these, the role of TG2 in
the gluten-induced enteropathy CD is best characterized. By
deamidating gluten peptides, TG2 is responsible for generating
immunogenic epitopes, which are recognized by disease-caus-
ing CD4 T cells in the context of HLA-DQmolecules, in par-
ticular the strongly disease-associated HLA-DQ2.5 variant (6).
In addition, TG2 is a target for autoantibodies in CD, and it is
believed that TG2-specific B cells are activated by gluten-spe-
cific CD4 T cells following B-cell uptake and presentation of
TG2-gluten complexes (7–11).We have previously generated a
panel of human anti-TG2 mAbs from plasma cells of celiac
patients (12). These antibodies displayed low mutation levels
but were yet highly specific to TG2. They were found to mainly
target four conformational epitopes clustered in the N-termi-
nal part of the enzyme, referred to as epitope 1–4 (13). Of these,
epitope 1 appears to be a dominant target across patients, which
may indicate that B cells recognizing this part of TG2 have an
advantage during activation (12, 13). None of the mAbs that
were tested blocked TG2 enzymatic activity. In line with this
observation, retention of TG2 activity is believed to be crucial
for activation of TG2-specific B cells (12, 14). However, it is not
yet known when or where these B cells are activated or where
TG2-mediated deamidation of gluten occurs, because TG2
activity in vivo appears to be tightly regulated (15).
TG2 is produced in the cytosol but can be transported to the
extracellular environment (16, 17), where it binds non-cova-
lently to the extracellular matrix. TG2 seems to have more
interaction partners in the extracellular matrix, but the high
affinity interaction with Fn is best characterized (18, 19). The
enzymatic activity requires binding of multiple Ca2 ions (1).
TG2 has six Ca2 binding sites (S1–S6), all located within the
catalytic core domain of the enzyme. A cooperative binding
modewas suggested for the binding of Ca2, indicating that the
initial binding induces allosteric changes that modulate addi-
tional binding (20). TG2 is susceptible to oxidative inactivation
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both in vitro and in situ in intestinal tissue sections (21–26).
TG2 activity in vivo also appears to be tightly regulated (15),
suggesting that TG2 in the extracellular environment may be
subject to redox regulation. Interestingly, oxidation does not
occur in the presence of saturating amounts of Ca2 (21). Oxi-
dative inactivation is believed to result from disulfide bridge
formation between Cys370 and either Cys230 or Cys371 (21).
Notably, Cys230 is located within the S1 Ca2 binding site.
Thus, binding of Ca2 and inactivation by oxidation involve the
same parts of TG2 and appear to be mutually exclusive events.
Crystallization studies have shown that TG2 exists in at least
two major conformations with different organization of the
four structural domains. Binding of GDP, GTP, or ATP causes
TG2 to adopt a “closed” conformation in which the two C-ter-
minal domains bend down toward the N-terminal domain and
fold over the active site in the catalytic core domain (27–29).
This form of TG2 is catalytically inactive and believed to be the
primary state intracellularly. In the presence of an active site
inhibitor, on the other hand, TG2 was crystallized in an “open”
conformation, where the four domains are aligned one after the
other with minimal interaction between them, and the active
site is exposed (30). The structure of TG2 in the presence of
Ca2 has not been solved. However, hydrogen/deuterium
exchange analysis suggested that binding of Ca2 induces
structural changes in the core domain and that these changes
are prevented by oxidation of the enzyme (31). In the absence of
externally added effectors, recombinant human TG2 displays a
heterogeneous conformation with a distribution of molecules
between the open and closed conformations. Importantly,
binding of anti-TG2mAbs displayed epitope-dependent induc-
tion of conformational changes in TG2, indicating that anti-
body binding may have hitherto unappreciated functional
effects on TG2.
In the present study, we address the effect of antibody bind-
ing on TG2 function by assessing oxidative inactivation and the
Ca2 sensitivity of the enzyme.We found thatmAbs binding to
epitope 1 consistently reduced oxidative inactivation and
increased Ca2 sensitivity of TG2. These effects were also
observed for 679-14-D04, which recognizes a previously
uncharacterized epitope. Here, we show that 679-14-D04 binds
to an epitope distinct from epitope 1 and that the shared effects
with epitope 1 mAbs are likely due to induction of similar con-
formational changes in TG2. Epitope 2 mAbs were found to
reduce the rate of TG2-mediated deamidation, an effect that
translated into less efficient uptake of TG2-gluten complexes
when comparing gluten peptide presentation by epitope 1- and
epitope 2-targeting transduced A20 B cells. Thus, the ability of
epitope 1-targeting B cells to keep TG2 active and protected
from oxidation might explain why generation of epitope 1-tar-
geting plasma cells seems to be favored in celiac patients.
Results
Antibodies Mediate Epitope-dependent Protection of TG2
from Oxidative Inactivation—To study enzymatic activity of
TG2, we measured TG2-mediated deamidation of a synthetic
gluten peptide by MALDI-TOF mass spectrometry under var-
ious conditions (21). Treatment of TG2 with GSSG induced
formation of intramolecular disulfide bonds and loss of activity
(Fig. 1A). Importantly, the activity could be restored by reduc-
tion with DTT as previously observed (21). We next addressed
the effect of preincubating TG2 with anti-TG2 mAbs targeting
different epitopes (12) prior to incubationwithGSSG (Table 1).
We observed that mAbs targeting epitope 1 (represented by
mAb 679-14-E06 in Fig. 1B) prevented loss of enzymatic activ-
ity. This effectwas not observed formAbs targeting epitope 2 or
epitope 3 (represented by mAbs 693-1-A03 and 763-4-A04,
respectively, in Fig. 1B). Of two mAbs recognizing previously
undefined epitopes, one (679-14-D05)was found not to have an
effect, whereas the other (679-14-D04) showed an even stron-
ger protective effect on oxidative inactivation than epitope 1
mAbs (Fig. 1C and Table 1). No effect was observed using non-
TG2 binding human mAbs or the mouse anti-TG2 mAb
CUB7402 (Fig. 1D andTable 1). The protective effect of epitope
1 mAbs and 679-14-D04 was observed over a range of concen-
trations and was comparable for full-length antibodies and for
Fab fragments (Fig. 1, E and F, respectively, and Table 1). The
protective effect of these mAbs was also observed by assessing
TG2 activity as transamidation of peptide substrate measured
by CE-LIF (Fig. 2). These data demonstrate that antibodies
binding to selected epitopes on TG2, including epitope 1, mod-
ulate the susceptibility of the enzyme to oxidative inactivation.
Binding of TG2 to FnDoesNot PreventOxidative Inactivation
despite Overlap with Epitope 1—It has previously been demon-
strated that epitope 1 overlaps with the Fn binding site of TG2
(13, 32). To address whether binding to Fn had a similar effect
as the epitope 1 mAbs, TG2 was preincubated with either full-
length Fn or a 45-kDa fragment of Fn that harbors the TG2
binding site (19, 33). Surprisingly, despite targeting overlapping
regions on TG2, preincubation of TG2 with Fn did not protect
TG2 from oxidative inactivation as observed for epitope 1
mAbs (Fig. 3 and Table 1). Thus, although epitope 1 overlaps
with the Fn binding site, epitope 1 likely includes additional
residues that may be crucial for the observed effect (34). Alter-
natively, the observed effect may derive from allosteric changes
in TG2 induced by epitope 1 mAbs but not by binding to Fn.
Epitope 1 mAbs and 679-14-D04 Increase the Ca2 Sensitiv-
ity of TG2—Because oxidation andCa2 binding appear to have
opposing effects on the structure ofTG2,we addressedwhether
the mAbs that prevent TG2 oxidation also affect the Ca2
requirements for enzymatic activity.We first determined Ca2
concentrations required for half-activity and full activity of
TG2 (Fig. 4A). Measuring gluten peptide deamidation, we
observed full activity of TG2 at 0.5 mM Ca2, which is in line
with previously reported values (35). We next determined TG2
activity at subsaturating concentrations of Ca2 (0.2mM) in the
presence of differentmAbs (Fig. 4B). Indeed, binding to epitope
1 mAbs and 679-14-D04 enhanced the activity of TG2 at this
Ca2 level, whereas other mAbs did not show this effect (Fig.
4B). Importantly, mAb binding was not sufficient to induce
TG2 activity, as the enzyme still required Ca2 to be catalyti-
cally active (not shown). The antibody-induced activity
increase was more pronounced at higher concentrations of
peptide substrate (Fig. 4, C and D). Thus, epitope 1 mAbs and
679-14-D04 appear to modify the deamidation rate by increas-
ing the Ca2 sensitivity of the enzyme.
Functional Properties of Anti-TG2 Autoantibodies
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Determination of the Binding Interface of TG2 and 679-14-
D04 by Site-directed Mutagenesis—We have previously shown
that epitope 1 mAbs and 679-14-D04 do not compete for bind-
ing to TG2 and that point mutations abrogating binding of
epitope 1 mAbs do not influence binding of 679-14-D04 (31,
34). However, we found that epitope 2 and epitope 3 mAbs can
compete with 679-14-D04 for binding (Fig. 5A), suggesting that
the epitope of 679-14-D04 partly overlaps with epitope 2 and 3.
Epitopes 1–4 depend on the N-terminal domain of TG2,
because they do not bind the chimeric protein TG3-TG2where
the N-terminal domain of TG2 is replaced by the N-terminal
domain of the homologous protein TG3 (36). However, this
protein is recognized by 679-14-D04 (Fig. 5B), indicating that
its epitope lies predominantly within the catalytic core domain
of TG2. To identify residues important for recognition, we
mutated selected positively or negatively charged residues in
the core domain in proximity to or within Ca2-binding sites
(20). We previously observed that binding of 679-14-D04
depends on TG2 conformation and that binding is stronger if
the enzyme is locked in an open conformation or preassociated
with Fn. To ensure optimal binding and equal conformation of
the TG2mutants, we therefore immobilized themutants on Fn
prior to incubation with 679-14-D04 and detection of bound
antibody by ELISA. Mutation of residues His441, Arg433, and
Arg458, which are in close proximity to the Ca2 binding sites
S5 (Arg433–Asp438 (20)) and S2B (Glu447–Glu454 (20)) did not
affect binding, whereas the double mutant D151A/E155A tar-
geting the S4 Ca2 binding site (Asp151–Glu158 (20)) displayed
dramatically reduced affinity for 679-14-D04 (Fig. 5C). Thus,
the effects on TG2 activity that we observed for 679-14-D04
could derive from antibody mimicking of Ca2 binding (Fig. 5,
D andE). Of note, epitope 1mAbs and 679-14-D04 have similar
effects on TG2 function, even though they bind non-overlap-
ping epitopes, and epitope 1 is not located within a Ca2 bind-
ing site. Binding to a Ca2 binding site is therefore not required
to achieve the antibody-induced effects on TG2 function that
we observe.
An additional finding from our mutagenesis studies was that
the TG2 mutant R458A was no longer recognized by mouse
anti-TG2 mAb CUB7402 in ELISA (Fig. 5F). This mAb was
described to recognize a linear epitope in the core domain of
TG2 consisting of residues 447–478 (37), in particular residues
451–454 as reported by Lai et al. (38). Our results, however,
indicate that residue Arg458 is important for binding to
CUB7402.
Binding of Both Epitope 1 mAbs and 679-14-D04 Induce a
closed TG2 Conformation—By monitoring the distribution of
TG2 molecules between open and closed conformations using
hydrogen/deuterium exchange mass spectrometry, we have
previously reported that anti-TG2 mAbs can alter the confor-
FIGURE 1.Deamidation activity of TG2 after oxidation in absence or presence ofmAbs. A, deamidation activity wasmeasured asmass shift of a substrate
gluten peptide (maximum shift is 2.0 Da, corresponding to full peptide deamidation) using TG2 that had either been oxidized (Ox.), kept in the reduced state
(Red.), or reactivated (React.) by first oxidizing and then reducing. B, activity of TG2 oxidized in the absence or presence of anti-TG2mAbs targeting epitope 1
(e1), 2 (e2), or 3 (e3).C, comparisonof thedeamidation activity of TG2after oxidation in thepresenceof 679-14-D04andepitope1mAbs.D, deamidation activity
of TG2 after oxidation in presence of the TG2 negative mAbs 679-14-E06H/679-14-A04L (E06H/A04L), and 679-14-A04H/679-14-E06L (A04H/E06L), which
harbor theheavyor light chainof the TG2-positivemAb679-14-E06pairedwith the light or heavy chainof the TG2-negativemAb679-14-A04. The results show
that presence of either heavy or light chain of an epitope 1 mAb is not sufficient to protect from oxidation. That is, specific binding to epitope 1 is needed to
preserve an effect. The effect of the epitope 1 mAb 679-14-E06, theTG2-negative mAb 693-2-F04, and mouse anti-TG2 mAb CUB7402 are also shown. E,
deamidation activity after 90 min. Oxidation in the presence of 4.8:1, 2.4:1, 1.2:1, or 0.6:1 molar ratios of mAb:TG2 has been carried out. F, comparison of TG2
deamidation activity after 90min after oxidation in the presence of mAbs and their corresponding Fab fragments. For A–D, representative results from one of
at least two experiments are shown. E and F were performed once except analysis of reduced and oxidized TG2 that was performed twice where error bars
indicate S.D.
Functional Properties of Anti-TG2 Autoantibodies
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mational state of TG2. Incubation with epitope 1 mAbs
changed the distribution in favor of a closed conformation,
whereas epitope 2 mAbs pushed the enzyme into an open con-
formation (31). Here, we have included additional mAbs in the
analysis and found that neither epitope 3 nor epitope 4 mAbs
had an effect on the distribution of TG2 molecules between
open and closed states. Interestingly, however, 679-14-D04
changed the distribution in favor of the closed state, similar to
what we observed for epitope 1 mAbs (Fig. 6). Thus, it is likely
that the shared functional effects of epitope 1 mAbs and 679-
14-D04 can be explained by the mAbs inducing similar confor-
mational changes in TG2 despite binding to separate epitopes.
Binding to Epitope 2 Decreases TG2 Deamidation Rate and
Impedes TG2-Peptide Complex Presentation to T Cells—When
measuring the activity of unoxidized TG2 in the presence of
anti-TG2 mAbs, we found that epitope 2 mAbs consistently
reduced the initial rate of gluten peptide deamidation, whereas
mAbs recognizing other epitopes did not have an effect (Fig. 7).
The strongest effects were observed for the epitope 2mAb 763-
4-B06 and themousemAbCUB7402. These observations are in
accordance with previous observations made in our lab where
we observed inhibitory effects of 763-4-B06 andCUB7402 in an
assay in which TG2 was preincubated with mAb before addi-
tion of substrate and Ca2 (12). In the previous analysis, the
remaining mAbs had no strong inhibitory effects. However,
some antibodies were weakly inhibitory, and all other epitope 2
mAbs were of this category. Thus, it appears that epitope 2
mAbs reduce the initial reaction rate, but they do not prevent
TG2-mediated deamidation. TG2 activity is believed to be cru-
cial for activation of TG2-specific B cells in CD, because the
active enzyme can form complexes with substrate gluten pep-
tides, thereby allowingBCR-mediated uptake of gluten byTG2-
specific B cells. Thus, following uptake of TG2-gluten com-
plexes, TG2-specific B cells can present deamidated gluten
peptides to T cells. We therefore tested whether the decreased
activity observed upon binding to epitope 2 would affect the
ability of epitope 2-targeting B cells to present deamidated glu-
ten peptide to T cells after incubation with TG2 and native
peptide. For this purpose, we generated transduced A20 B cells
expressing HLA-DQ2.5, together with a BCR targeting epitope
1 or 2, membrane-bound 679-14-D04 or a TG2-negative BCR
(Fig. 8A). When TG2 was present in solution, all TG2-reactive
cells were able to take up TG2-gluten complexes and present
deamidated gluten peptide to T cells (Fig. 8B, left panel). How-
ever, when excess TG2 in solution was washed away prior to
incubation with gluten peptide, only cells expressing 679-14-
D04 or epitope 1 BCR efficiently presented peptide to T cells,
suggesting that TG2, which was bound to the epitope 2 BCR,
did not readily form complexes with gluten (Fig. 8B, right
panel). Based on these observations, it is conceivable that the
decreased activity associated with epitope 2 binding can be
explained by destabilization of the enzyme-substrate interme-
diate formed between TG2 and gluten peptide so that such
FIGURE 2. Transamidation activity of TG2 after oxidation in presence of
mAbs. Transamidation of a FITC-labeled gluten-peptide after oxidation of
TG2 determined at a single time point (15 min) in the absence or presence
of mAbs recognizing epitope 1 (e1), 2 (e2), 3 (e3), or 4 (e4) or 679-14-D04. The
plotted values represent total modification, including both deamidation and
transamidation. Oxidation was carried out for 30 min, whereas 60 min of
oxidation was used for the deamidation assay shown in Fig. 1, explaining the
greater residual activity for oxidized TG2 in this assay. Representative results
from one of two experiments are shown.
FIGURE 3. Effect of Fn on TG2 activity after oxidation. TG2 deamidation
activity after oxidation in the presence of Fn is plotted as mass shift of the
substrate gluten peptide. Activity of oxidized (ox) and reduced (red) TG2 in
the absence of Fn is shown for comparison. Representative results from one
of two experiments are shown.
TABLE 1
TG2deamidation activity after oxidation in the presence ofmAbs, Fab
fragments, or fibronectin
Fab, Fab fragment; , TG2 (partly) active after oxidation; , TG2 not active after
oxidation.
TG2 Epitope
Observed deamidation
activity
/ 
mAb 679-14-E06 1 
Fab 679-14-E06 1 
mAb 693-10-B06 1 
Fab 693-10-B06 1 
mAb 763-4-C06 1 
mAb 693-1-B06 1 
mAb 679-14-A05 1 
mAb 693-1-F06 2 
Fab 693-1-F06 2 
mAb 693-1-A03 2 
mAb 763-4-B06 2 
mAb 693-10-A05 2 
mAb 763-4-A06 3 
mAb 693-1-B03 3 
mAb 693-1-E01 3 
mAb 693-10-A06 3 
mAb 693-1-D03 4 
mAb 679-14-D04 
Fab 679-14-D04 
mAb 679-14-D05 
Fn 
45-kDa Fn 
TG2 neg mAb 693-2-F04 
mAb 679-14-E06H/679-14-A04L 
mAb 679-14-A04H/679-14-E06L 
Mouse mAb CUB7402 
Functional Properties of Anti-TG2 Autoantibodies
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complexes cannot be taken up efficiently by TG2-specific B
cells.
Although both 679-14-D04 and epitope 1 BCR allowed
bound TG2 to react with gluten, only the latter was efficiently
cross-linked to a fluorescently labeled gluten peptide through
TG2-mediated transamidation (Fig. 8C). This finding is in
agreement with previous observations showing that epitope 1
mAbs, but not 679-14-D04, are efficiently cross-linked by TG2,
FIGURE 4. Effect of 679-14-D04 and 679-14-E06 (epitope 1) on the Ca2 sensitivity of TG2. A, deamidation activity of TG2 at various Ca2 concentrations
was determined as substrate peptide mass shift after 60 min of incubation. B, TG2 activity at 0.2 mM Ca2 in the presence of various anti-TG2 mAbs targeting
epitopes 1or 2 (e1 and e2, respectively) or not previously assigned to adefinedepitope.C andD, TG2 activity over timeusingdifferent substrate concentrations
in the presence or absence of mAb 679-14-E06 (C) and 679-14-D04 (D). The experiments shown in each panel were done in parallel at a Ca2 concentration of
0.2 mM. For A and B, representative results from one of two experiments are shown.
FIGURE 5. Binding interface of TG2 and 679-14-D04. A, competition between 679-14-D04 expressed as IgG1 and mAbs 679-14-E06 (epitope 1), 693-1-F06
(epitope 2), and 693-1-E01 (epitope 3) expressed as IgA1. Binding is given as the measured IgG1 ELISA signal relative to the signal obtained in the absence of
competing IgA1mAbs. B, binding of 679-14-D04 to the chimeric protein TG3/TG2, which harbors the N-terminal domain of TG3 and the catalytic core domain,
aswell as the twoC-terminal domainsof TG2.C, bindingof 679-14-D04 to theTG2doublemutantD151A/E155Aand theTG2 singlemutantsH441A, R433A, and
R458A immobilized on Fn.D, structure of TG2 (PDB code 1KV3) (28)with indication of knownCa2-binding sites (20) (orange), location of the epitopes 1, 2, and
3 (blue, cyan, andmagenta, respectively) and residuesmutated in this study (residues Asp151 andGlu155 in red and residues His441, Arg433, andArg458 in purple).
E, close-up of the identified epitope of 679-14-D04 (red). The location of nearby Ca2-binding sites (orange) are also shown. F, binding of the mouse anti-TG2
mAb CUB7402 to the TG2mutants D151A/E155A, H441A, R433A, and R458A immobilized on Fn. For A–C and F, representative results from one of at least two
experiments are shown.
Functional Properties of Anti-TG2 Autoantibodies
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because binding via epitope 1 allows TG2 to act on the same Ig
molecule to which the enzyme is bound (14). TG2-mediated
cross-linking of gluten peptides to the BCR could be an alter-
native pathway for uptake of gluten by TG2-reactive B cells.
Such a mechanism would thus give epitope 1 B cells an advan-
tage over B cells targeting other TG2 epitopes, including the
epitope of 679-14-D04.
Discussion
This work illustrates that activity and structure of TG2 are
influenced by interactionwith antibodies. Specifically, we dem-
onstrate that celiac anti-TG2 mAbs targeting epitope 1 modu-
late TG2 activity both by preventing susceptibility to oxidative
inactivation and by increasing Ca2 sensitivity of the enzyme.
These two effects are likely interrelated, because Ca2 binding
and oxidative inhibition appear to be opposing events. Thus,
Ca2-induced conformational changes observed in unoxidized
TG2 did not occur when the oxidized enzyme was incubated
with Ca2, indicating that generation of disulfide bridges in the
core domain interferes either with binding of Ca2 or Ca2-
induced structural changes required for enzymatic activity (31).
In agreement with this finding, oxidation of Cys230, Cys370, and
Cys371 did not occur in the presence of saturating concentra-
tions of Ca2 (21).
The effects on TG2 function observed for epitope 1 mAbs
were also seen for one other mAb in our panel, 679-14-D04.
This mAb targets an epitope that is distinct from epitope 1, and
it showed even stronger effects on TG2 function than epitope 1
mAbs. Here, we have mapped the epitope of 679-14-D04 to
the catalytic core domain of TG2 and found that it coincides
with a Ca2 binding site. Despite targeting separate epitopes,
we show that epitope 1 mAbs and 679-14-D04 induce similar
conformational changes in TG2, which likely explains their
shared effects on TG2 function. Epitope 2 mAbs, on the
other hand, had a clearly different effect on TG2 conforma-
tion and were found to reduce the initial rate of TG2-medi-
ated deamidation.
The role of antibodies in the development of CD is still
unclear, and caution should be exercised in interpreting our
observations in relation to CD pathogenesis. Notwithstanding,
we would like to discuss some potentially important aspects.
The differential effects of antibodies targeting different epi-
topes may explain why studies using polyclonal anti-TG2 sera
from CD patients show conflicting and inconclusive results
regarding the effects of antibodies on TG2 catalytic function
(37, 39–50). Although our observations indicate that celiac
anti-TG2 antibodies may modulate extracellular TG2 activity,
our incomplete understanding of TG2 biology and activity in
the extracellularmatrixmakes it difficult to properly assess this.
In contrast, such effects are likely more important at the B-cell
level. The different effects of epitope 1 and epitope 2 mAbs on
TG2 conformation and activity translated into less efficient
internalization and presentation of gluten peptides by A20 B
cells transduced with an epitope 2 anti-TG2 BCR compared
with cells expressing an epitope 1 or 679-14-D04 anti-TG2
BCR. Thus, B cells with a BCR that supports or retains TG2
activity through favorable conformational changes will receive
more T cell help from gluten-specific T cells. Our findings may
FIGURE 7. TG2 activity in the presence of mAbs targeting different
epitopes. Shown is deamidation activity of TG2 alone or after 20 min of pre-
incubation at room temperature with mAbs targeting different epitopes,
including the previously characterized epitopes 1 (e1), 2 (e2), 3 (e3), and 4 (e4).
The mouse anti-TG2 mAb CUB7402 is also included. Activity was plotted as
the mass shift of substrate gluten peptide. Representative data from one of
two experiments are shown.
FIGURE 6. Deconvoluted mass spectra of deuterated TG2 labeled in the
absence or presence of mAbs targeting different epitopes. The distribu-
tion of TG2molecules betweenopen and closed conformationswas assessed
by incubating TG2with orwithoutmolar excess of anti-TG2mAbs in 90%D2O
for 1000 s followed by detection of intact TG2 by mass spectrometry. After
incubation in D2O, the mass of the enzyme increases in a conformation-de-
pendentmanner as a result of backbone amide hydrogens being exchanged
with deuterium (deuteration). The spectra shown for TG2 incubated without
mAbs and together with epitope 1 and epitope 2mAbs have been published
previously (31). Detection and analysis were performed twice.
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therefore explain why epitope 1 antibodies appear to dominate
the anti-TG2 response in CD patients.
The fact that antibodies targeting the same epitope as 679-
14-D04 have not previously been described in CD is surprising,
because B cells with this specificity presumably also should
have an advantage in competition for T-cell help. One explana-
tion for why only epitope 1 seems to be favored could be that
epitope 1-targeting B cells acquire an additional advantage
through binding of TG2 in an orientation that allows enzymatic
cross-linking of gluten peptides to the BCR and, hence, more
efficient gluten presentation as recently proposed (14). Indeed,
we found that TG2 cross-linked gluten peptidemore efficiently
to epitope 1 BCR than epitope 2 BCR or membrane-bound
679-14-D04. Alternatively, epitope 1-targeting antibodies
are more prominent because they are made up of stereotypic
combinations of variable region gene segments with inher-
ent TG2 reactivity. Thus, it was shown that most epitope 1
antibodies contain heavy chains using the IGHV5-51 gene
segment in combination with certain light chain IGKV seg-
ments (13) and that these antibodies are commonly gener-
ated in CD patients (51). Precursor B cells targeting epitope
1 could therefore be more frequent than B cells targeting the
epitope of 679-14-D04. It is also possible that B cells target-
ing certain TG2 epitopes are more likely to undergo negative
selection because of self-reactivity than other TG2-reactive
B cells and therefore occur less frequently in the B-cell pop-
ulation or require stronger stimulation to differentiate into
plasma cells.
In summary, we have found that celiac antibodies targeting
certain epitopes can affect both the deamidation and transami-
dation activity of TG2 by protecting the enzyme from oxidative
inactivation and by increasing its Ca2 sensitivity. These effects
may have implications for the activation TG2-reactive B cells
and help explain why one epitope seems to be preferred among
TG2-targeting plasma cells in CD. Interestingly, it was recently
shown that a subset of antibodies targeting the Ca2-depen-
dent enzyme PAD4 in rheumatoid arthritis increase the Ca2
sensitivity of the enzyme (52). Thus, themechanisms described
here for CDmight also apply to other autoimmune conditions,
and antibody- or BCR-mediated modulation of the catalytic
function of a target enzyme might be a key step in establishing
an autoantibody response.
FIGURE 8. Effects of epitope targeting on TG2-reactive B cells. A, flow histograms showing TG2 binding by transduced A20 B cells expressing TG2-reactive
(679-14-E06, 693-1-F06, and 679-14-D04) or TG2-negative (693-2-F02) IgD BCR. The cells were either stained with biotinylated TG2 attached to phycoerythrin
(PE)-conjugated streptavidin (black lines) or with phycoerythrin-streptavidin alone (gray areas). B, collaboration between A20 cells expressing the indicated
BCRs and gluten-specific hybridoma T cells assessed by release of IL-2 from the hybridoma cells. The A20 cells were incubated with gluten peptide and active
TG2 present either in solution or bound to the BCR. C, TG2-mediated cross-linking of a fluorescently labeled gluten peptide to surface IgD molecules on A20
cells assessed by detection of fluorescent gel bands in cell lysates (left panel). TG2-reactivemembrane-bound IgDheavy chains have previously been shown to
serve as theprimary target of TG2-mediated cross-linkingon the surfaceof transducedA20cells (14). Following fluorescencedetection, the total amountof IgD
BCR in each sample was revealed byWestern blotting using rabbit anti-human IgD followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (right
panel). For all panels, representative results fromone of two experiments are shown. In B, each peptide concentrationwas analyzed in triplicates. The error bars
indicate S.D. The different cells were compared by two-way analysis of variance using GraphPad Prism software. Peptide concentrations for which either
679-14-E06 or 679-14-D04 BCR gave significantly higher IL-2 production than 693-1-F06 BCR are indicated with * (p  0.05) or ** (p  0.001). Peptide
concentrations forwhichboth679-14-E06 and679-14-D04BCRgave significantly higher IL-2 production than693-1-F06BCRare indicatedwith *** (p0.001).
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Experimental Procedures
Production and Purification of Anti-TG2Autoantibodies and
Fab Fragments—Cloning, expression, and purification of anti-
TG2 mAbs was done as described previously (34). Unless oth-
erwise indicated, the used mAbs were expressed as full-length
human IgG1molecules. Fab fragments were cloned with a sim-
ilar procedure as previously described for Fab 679-14-E06 (34)
by adding a stop codon after hinge residue 6 (2PKSCD6, accord-
ing to the ImMunoGeneTics numbering scheme) and purified
using a protein L column (GE Healthcare) applying the previ-
ously reported protocol for antibody purification. Selected
mAbs representing epitope 1, 2, or 3 were engineered as human
IgA1 by overlap extension PCR using the IgA1 version of mAb
679-14-E06 (12) as a constant region template, followed by sub-
cloning into the expression vector between the AgeI and Hin-
dIII restriction sites. IgA1 mAbs were purified on protein L.
TG2 Variants—Recombinant human TG2 produced in
insect cells (obtained from Phadia) was used for all activity
assays and in the hydrogen/deuterium exchange experiments.
For comparison of WT and mutant TG2 by ELISA, recombi-
nant enzyme produced in Escherichia coli was used (21, 31).
Mutations were introduced into TG2 with the QuikChange
site-directed mutagenesis kit (Stratagene) and produced and
purified as previously described (34). Chimeric TG3/TG2 com-
prising the N-terminal domain of TG3 (residues 1–136) fused
to the core andC-terminal domains of TG2 (residues 141–687)
was generated by overlap extension PCR followed by subclon-
ing into the pET-28a vector (Novagen) between the NdeI and
HindIII restriction sites. Biotinylated TG2 used for flow cytom-
etry was generated from E. coli-producedTG2 harboring a site-
specific biotinylation BirA tag between theHis tag and the TG2
sequence. The BirA tag was introduced by PCR amplification
followed by subcloning into the pET-28a vector between the
NcoI and HindIII restriction sites, and biotinylation of purified
TG2was carried out using the BirA biotin-protein ligase (Avid-
ity) according to the instructions from the manufacturer.
Oxidation of TG2—To address the possible effect of anti-
TG2 mAbs on oxidation of TG2, 24.6 pmol of TG2 was incu-
bated with or without 60 pmol of mAb, 120 pmol of Fab frag-
ment, or 30 pmol of Fn for 20 min at room temperature in
activity buffer (100mMTris-HCl, pH 7.4) and then oxidized for
1 h (for mass spectrometry measurements) or 30 min (for cap-
illary electrophoresismeasurements) at 37 °C in the presence of
4mMGSSG. Control samples were incubated for 1 h at 37 °C in
the presence of 2 mM DTT. Reactivated samples were first oxi-
dized as described above before incubationwith 10mMDTT for
30 min at room temperature.
Determination of Enzymatic Activity by MALDI-TOF Mass
Spectrometry—TG2 (0.037 g/ml) treated as described above
was incubated at 37 °C with 12M of a synthetic gluten peptide
(PQPQ LPYPQPQLPY, where the underlined residues denote
glutamine residues targeted by TG2, obtained from GL
Biochem) in the presence of 10 mM CaCl2. Alternatively, TG2
was incubatedwith 30Mof the peptide and 10mMCaCl2when
addressing the initial rate of peptide deamidation in the pres-
ence of mAbs. At the indicated time points, 2–2.5 l of the
reaction mixture was quenched with an equal volume of 0.2%
(v/v) TFA, and the quenched samples weremixed 1:1 (v/v) with
5 mg/ml -CHCN matrix. Measurements were performed on
an Ultraflex II MALDI-TOF mass spectrometer (Bruker Dal-
tonics). For each sample, 8 measurements of 200 shots were
combined before the calculated centroid mass of a non-deami-
dated peptide control was subtracted from the determined cen-
troidmass of the samples to obtain themass shift introduced by
deamidation. To address the effect of epitope 2 mAbs on TG2
deamidation activity without prior oxidation or reduction, the
enzyme was preincubated with mAb as described above, fol-
lowed by incubation at 0.037 g/ml with 24 M peptide and
measurement of deamidation.
Determination of Enzymatic Activity by CE-LIF—CE-LIF
measurements were performed by capillary zone electrophore-
sis (Agilent Capillary Electrophoresis System), which was cou-
pled to an external laser-induced fluorescence detector (488
nm; Zetalif Evolution, Picometrics) using a modified method
previously described by Stamnaes et al. (21). Native and modi-
fied (deamidated and transamidated) peptides were separated
in a capillary of fused silica (75-m inner diameter, 50-cm
total length, 0.5-cm window for laser induction after 35 cm)
after washing of the capillary with 1 MNaOH (15min) andH2O
(15 min) and equilibrating with running buffer (60 mM borate,
20 mM SDS, pH 9.3) (30 min). TG2-mediated transamidation
of a FITC-labeled gluten peptide (FITC-Acp-PQPELPYPQP
QLPY, where the underlined residue denotes the glutamine
residue targeted by TG2, obtained from GL Biochem) and the
amine donor 5-(biotinamido)pentylamine was assessed at the
indicated time points by measuring the area under the peaks of
the resulting electropherograms. The peptide was incubated at
40 M with or without (deamidation control) 400 M 5-(bioti-
namido)pentylamine in the presence of 0.037 g/ml TG2 and
10 mM CaCl2 in activity buffer at 37 °C. At each time point, 2.5
l of the reaction mixture was taken out and kept at 20 °C
untilmeasurement. The samples were diluted in running buffer
to give a total volumeof 100l and injected by 50mbar pressure
for 2 s. Measurements were performed at 25 °C with 20 kV and
100 A using an electro-osmotic flow from cathode to anode.
Ca2 Sensitivity of TG2 in the Presence of mAbs—Possible
effects of anti-TG2 mAbs on TG2 Ca2 sensitivity were
assessed using the peptide deamidation assay described above.
TG2 (24.6 pmol) was preincubated with or without mAb (60
pmol) for 20 min at room temperature in activity buffer before
the enzymewas incubated at 0.037g/mlwith 12Mof peptide
in the presence of 0.2 mM CaCl2 at 37 °C. The optimal Ca2
concentration used in the assay was initially determined by
titrating the CaCl2 concentration.
ELISAs—For comparison of mAb binding to WT and single
or double TG2 mutants, TG2 (3 g/ml) was attached to a
coated 45-kDa Fn (5 g/ml) obtained from Sigma, whereas
binding to chimeric TG3/TG2was assessed after direct coating
of the inhibitor-bound enzyme (3 g/ml). Irreversible binding
to inhibitor was done to make the enzyme obtain an open con-
formation. To achieve this, TG2 was incubated with 0.5 mM of
the inhibitor Ac-P(DON)LPF-NH2 (where DON is the electro-
philic amino acid 6-diazo-5-oxo-L-norleucine, obtained from
Zedira) for 20min at room temperature, followed by addition of
CaCl2 to a final concentration of 5 mM and incubation for
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another 20 min. Coating was carried out overnight at 4 °C in
TBS, whereas TBS containing 0.1% Tween 20 was used for
washing and incubation steps. Incubations were done at 37 °C.
Binding to TG2 captured on the 45-kDa Fn was assessed us-
ing mAbs biotinylated with EZ-link sulfo-NHS-LC-biotin
(Thermo Scientific) according to the manufacturer’s instruc-
tions, followed by detection with alkaline phosphatase-conju-
gated streptavidin (Southern Biotech). When TG2 was coated
directly, bound mAb was detected using alkaline phosphatase-
conjugated goat anti-human IgG (Southern Biotech). Compet-
itive ELISA experiments were carried out by incubating coated
inhibitor-bound TG2 (produced in insect cells) with anti-TG2
IgA1 mAbs targeting different epitopes for 30 min at 37 °C.
Without removing the IgA1 mAbs, 679-14-D04 expressed as
IgG1 was added to a final concentration of 0.03 g/ml, and
incubation was continued for 1 h. Detection of bound 679-14-
D04 was carried out as described above.
T-Cell/B-cell Collaboration Assay—T-cell activation mea-
sured by release of IL-2 was used to assess B-cell uptake and
presentation of TG2-gluten complexes. Murine A20 B lym-
phoma cells expressing HLA-DQ2.5 and 679-14-D04 IgD BCR
were generated by retroviral transduction as previously
described for the other BCRs using codon-optimized synthetic
DNA (GenScript) (12, 14) A20 cells expressing HLA-DQ2.5
and TG2-reactive (679-14-E06, 693-1-F06, or 679-14-D04) or
TG2-negative (693-2-F02) IgD BCR (14) were incubated at 10
million cells/ml with a combination of TG2 (1.2 g/ml), CaCl2
(2 mM), and various concentrations of a 33-mer gluten pep-
tide (LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF, where
underlined residues denote glutamine residues targeted by
TG2, obtained from GL Biochem) in RPMI for 1 h at 37 °C.
Alternatively, the cells were preincubated with TG2 in PBS for
30min on ice andwashedwith PBS to remove non-BCR-bound
TG2. Washed cells were resuspended in RPMI and supple-
mented with CaCl2 and peptide prior to incubation at 37 °C as
described above. The cells were then washed with RPMI to
remove free peptide, resuspended at 1 million cells/ml in 5%
(v/v) FCS/RPMI, and incubated for 3 h at 37 °C. 25,000
hybridoma T cells specific to the deamidated DQ2.5-glia-2
epitopewere then added to 100,000A20 cells, and the cells were
cultured together at 37 °C. The next day, culture supernatants
were collected and assayed for murine IL-2 secretion by ELISA
as previously described (53). IL-2 concentrations were calcu-
lated from a standard curve generated using recombinant
murine IL-2 (BioLegend).
Flow Cytometry—To assess the TG2 binding capacity of
transducedA20 cells, the cells were stainedwithTG2 tetramers
for 30 min on ice and analyzed on a FACSCalibur flow cytom-
eter (BD). The tetramerswere generated by incubating 4.5g of
biotinylated TG2 with 2 g of phycoerythrin-conjugated
streptavidin (Thermo Scientific) in 250l 2% (v/v) FCS/PBS for
2 h on ice.
TG2-mediated Cross-linking of BCR Molecules—To assess
the ability of TG2 to cross-link IgD BCRs targeting different
epitopes to gluten peptide, 50 million transduced A20 cells
were incubated with 1.5 g of TG2 in 500 l of PBS for 30 min
on ice, followed by washing with PBS to remove free TG2 and
resuspension in 500 l cold RPMI. A fluorescently labeled glu-
ten peptide (FITC-Acp-PQPQLPYPQPQLPY, obtained from
GL Biochem) was added to a final concentration of 40 M, and
CaCl2 was added to 5mM to initiate cross-linking. The reaction
was allowed to proceed for 1 h on ice before the cells were
washed with cold PBS and lysed with 750 l of 1% (w/v) n-do-
decyl--D-maltoside, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0,
supplemented with COmplete protease inhibitor mixture
(Roche) for 1 h at 4 °C. The lysate was centrifuged at maximum
speed for 15 min at 4 °C in a microcentrifuge. BCR molecules
were pulled down from the supernatant by incubationwith pro-
tein L-agarose (GenScript) for 1 h at 4 °C, followed by elution
with SDS-PAGE sample buffer containing 2-mercaptoethanol.
The samples were run on a 12% polyacrylamide gel (Bio-Rad),
and fluorescent bands were detected using a ChemiDocMP gel
imager (Bio-Rad). Total BCR levels were subsequently detected
by Western blotting as previously described (14).
Hydrogen/Deuterium Exchange—The distribution of TG2
molecules between open and closed conformations was
assessed by hydrogen/deuterium exchange monitored by mass
spectrometry as previously described (31). Briefly, TG2 was
preincubated in the presence or absence of mAbs targeting dif-
ferent epitopes in TBS. Labeling was initiated by addition of
buffer made with D2O to 90% (v/v) and stopped by addition of
formic acid and freezing in liquid nitrogen. The samples were
analyzed in duplicates using a Waters HDX Manager in con-
junction with a Waters Synapt G1 mass spectrometer.
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